Reduced antithrombin III levels during L‐asparaginase therapy

G. R. Buchanan, C. A. Holtkamp

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Antithrombin III levels were measured in serum before, during, and after therapy with three different dosage regimens of L‐asparaginase in 11 children with acute lymphoblastic leukemia. Levels determined by both functional and immunologic methods were transiently reduced during alternate‐day or daily L‐asparaginase treatment but not affected when the drug was administered only every 10 days. The probable mechanism of this effect is impaired hepatic synthesis of antithrombin III, resembling the acute and transient deficiency of other asparagine‐rich proteins during L‐asparaginase administration.

Original languageEnglish (US)
Pages (from-to)7-14
Number of pages8
JournalMedical and Pediatric Oncology
Issue number1
StatePublished - 1980


  • L‐asparaginase
  • antithrombin
  • coagulation
  • leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Reduced antithrombin III levels during L‐asparaginase therapy'. Together they form a unique fingerprint.

Cite this